We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Atreca Inc | NASDAQ:BCEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.15 | 0.16 | 0.17 | 0 | 01:00:00 |
"In the first quarter of 2023 we continued to advance both ATRC-101 and our preclinical programs. The additional data from the ongoing Phase 1b study of ATRC-101 that we reported in March will help inform our anticipated go / no-go decision for Phase 2 development, which remains on-track for later this year,” said John Orwin, Chief Executive Officer of Atreca. “We continue to invest strategically in our platform, which has supported an acceleration of our discovery and early-stage development efforts. We are making great progress in advancing both the APN-497444 and APN-346958 programs and continue to anticipate nominating clinical candidates for both programs later this year.”
Recent Developments and Highlights
First Quarter and 2023 Financial Results
About Atreca, Inc.Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, our pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.
Forward-Looking StatementsThis release contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, our preclinical and clinical plans and the timing thereof, including plans to nominate clinical candidates from APN-497444 and APN-346958 in 2023, the progress and timing of our Phase 2 development and the timing of data read-outs thereof, the acceleration of our discovery and early-stage development efforts and progress related to our APN-497444 and APN-346958 programs. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Atreca, Inc. | ||||||||
Balance Sheets | ||||||||
(in thousands, except share and per share data) | ||||||||
March 31, | December 31, | |||||||
2023 | 2022 | |||||||
(unaudited) | ||||||||
ASSETS | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 39,484 | $ | 30,819 | ||||
Investments | 16,904 | 39,676 | ||||||
Prepaid expenses and other current assets | 3,255 | 7,531 | ||||||
Total current assets | 59,643 | 78,026 | ||||||
Property and equipment, net | 36,671 | 37,972 | ||||||
Operating lease right-of-use assets | 35,618 | 36,056 | ||||||
Deposits and other | 2,494 | 2,976 | ||||||
Total assets | $ | 134,426 | $ | 155,030 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 1,400 | $ | 1,741 | ||||
Accrued expenses | 7,890 | 9,681 | ||||||
Operating lease liabilities, current portion | 3,655 | 3,544 | ||||||
Other current liabilities | 1,121 | 1,327 | ||||||
Total current liabilities | 14,066 | 16,293 | ||||||
Operating lease liabilities, net of current portion | 59,394 | 60,331 | ||||||
Total liabilities | 73,460 | 76,624 | ||||||
Stockholders’ equity | ||||||||
Class A common stock | 3 | 3 | ||||||
Class B common stock | 1 | 1 | ||||||
Additional paid-in capital | 538,924 | 535,592 | ||||||
Accumulated other comprehensive (loss) | (28 | ) | (266 | ) | ||||
Accumulated deficit | (477,934 | ) | (456,924 | ) | ||||
Total stockholders’ equity | 60,966 | 78,406 | ||||||
Total liabilities and stockholders’ equity | $ | 134,426 | $ | 155,030 | ||||
Atreca, Inc.Statements of Operations(in thousands, except share and per share data)(unaudited) | |||||||||
Three Months Ended | |||||||||
March 31, | |||||||||
2023 | 2022 | ||||||||
Expenses | |||||||||
Research and development | $ | 13,452 | $ | 17,064 | |||||
General and administrative | 8,079 | 8,606 | |||||||
Total expenses | 21,531 | 25,670 | |||||||
Interest and other income (expense) | |||||||||
Other income | 92 | 750 | |||||||
Interest income | 429 | 44 | |||||||
Loss before Income tax expense | (21,010 | ) | (24,876 | ) | |||||
Income tax expense | - | - | |||||||
Net loss | $ | (21,010 | ) | $ | (24,876 | ) | |||
Net loss per share, basic and diluted | $ | (0.54 | ) | $ | (0.65 | ) | |||
Weighted-average shares used in computing net loss per share, basic and diluted | 39,092,167 | 37,982,863 | |||||||
Contacts
Atreca, Inc.Herb CrossChief Financial Officerinfo@atreca.com
Investors:Alex Gray, 650-779-9251agray@atreca.com
Media:Julia Fuller, 858-692-2001julia@fordhutmanmedia.com
1 Year Atreca Chart |
1 Month Atreca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions